Author: Bill Snyder
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
VUMC team aids development of potential antiviral drug for COVID-19
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Study aims to shield health workers from COVID-19 infection
Apr. 2, 2020—VUMC is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.
Researchers developing potential coronavirus antibody therapies
Mar. 23, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Blocking stress-induced relapse
Mar. 19, 2020—Danny Winder and colleagues are teasing apart the actions of neurotransmitter receptors in a brain region linked to anxiety and addiction, with a goal of finding treatments for substance use disorders.
Ibuprofen and COVID-19: a doctor’s guidance
Mar. 18, 2020—Last week, France’s health ministry urged people who have been infected by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) to avoid taking over-the- counter nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and aspirin because they might increase the severity of the infection.
UC Berkeley’s Doudna named to receive Vanderbilt Prize
Mar. 18, 2020—Jennifer Doudna, PhD, who led development of the revolutionary genome editing technology known as CRISPR-Cas9, is the recipient of the 2020 Vanderbilt Prize in Biomedical Science, officials at Vanderbilt University Medical Center announced this week.
Triple-negative breast cancer drug therapy shows promise
Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Clinical investigation society lauds Vanderbilt scientists
Mar. 12, 2020—Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:
Neurotransmitter expert Amara set for March 12 Discovery Lecture
Mar. 4, 2020—Susan Amara, PhD, scientific director of the Intramural Research Program at the National Institute of Mental Health (NIMH) and an expert on the biology of neurotransmitter transporters, will deliver the next Flexner Discovery Lecture on Thursday, March 12.
Breast cancer study may help predict treatment response
Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Potential new heartburn drug studied at VUMC
Feb. 26, 2020—An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.
